ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Nonalcoholic Steatohepatitis (NASH): 2021 Update Bulletin with Views & Insights from 3 World Leading KOLs; Intercept Pharmaceuticals, Madrigal Pharmaceuticals, and GENFIT - ResearchAndMarkets.com

December 30, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Dec 30, 2021--

The “Nonalcoholic Steatohepatitis (NASH): Update Bulletin” newsletter has been added to ResearchAndMarkets.com’s offering.

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in NASH market, including; Intercept Pharmaceuticals announcing the initiation of the global Phase III REVERSE study to evaluate the efficacy and safety of obeticholic acid (OCA; Ocaliva); Madrigal Pharmaceuticals reports positive top-line data from a Phase II clinical trial assessing MGL-3196 and GENFIT announcing the launch of the first clinical study in paediatric NASH patients to evaluate safety and efficacy of its dual PPARa/d agonist elafibranor.

ADVERTISEMENT

Business Questions:

  • What are KOL’s current views on obeticholic acid (OCA; Ocaliva) and what would they like to see from longer-term data?
  • How do KOLs view the studies in the cirrhotic NASH patients given safety concerns with Ocaliva in PBC setting?
  • Do KOLs think OCA can meet its primary endpoint in the REVERSE study?
  • How do KOLs think OCA, if approved for NASH, is likely to be priced?
  • How do KOLs rate the potential of Madrigal’s MGL-3196?
  • Where is MGL-3196 best likely to fit into the treatment strategy? What do KOLs say?
  • How do KOLs art the development of elafibranor in paediatric NASH?
  • What concerns do experts have with elafibranor in children?
  • What are KOLs expecting from the Phase III RESOLVE-IT study for elafibranor?

For more information about this newsletter visit https://www.researchandmarkets.com/r/qz9chr

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20211230005174/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 12/30/2021 09:03 AM/DISC: 12/30/2021 09:03 AM

http://www.businesswire.com/news/home/20211230005174/en